Mantle Cell Lymphoma

GLPG5101 produced responses and had a manageable safety profile in relapsed/refractory non-Hodgkin lymphoma, including mantle cell lymphoma.

Acalabrutinib plus rituximab followed by brexu-cel was safe and delivered responses in previously untreated, high-risk mantle cell lymphoma.

Hematology experts share the MCL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.

The FDA approved a new option in resectable gastric cancer, and a new agent is under priority review in mantle cell lymphoma.

Sonrotoclax is under priority review by the FDA for the treatment of adult patients with relapsed or refractory, BTK inhibitor–pretreated MCL.

Christine Ryan, MD, discusses the limitations of current MCL treatment strategies, advances in treatment, and the evolving role of BTK inhibition.

Liso-cel was approved in the EU for relapsed/refractory MCL after at least 2 lines of therapy, including a BTK inhibitor.

Carlo Visco, MD, discusses phase 2 FIL_V-RBAC results showing venetoclax plus RBAC achieved a meaningful PFS and manageable toxicity in high-risk MCL.

A meta analysis found BTK inhibitors carry risks of hypertension, atrial fibrillation, and hemorrhage, underscoring the need for cardiovascular monitoring.

The FDA granted breakthrough therapy designation to sonrotoclax for relapsed/refractory mantle cell lymphoma.

Real-world MCL treatment with zanubrutinib generated longer treatment durations and higher treatment adherence rates vs acalabrutinib and ibrutinib.

The removal of REMS programs for approved CAR T-cell therapies could enable improved access and streamlined management of hematologic malignancies.

Ibrutinib plus rituximab showed a progression-free survival benefit vs standard chemoimmunotherapy in older patients with untreated mantle cell lymphoma.

Patients with MCL who relapsed after brexu-cel had poor survival outcomes, underscoring the need for effective post–CAR T-cell therapy strategies.

Ruby Arora, MD, discusses ​​the declining incidence of MCL in the US, as well as ways to address disparities that remain in MCL management.

Martin Dreyling, MD, PhD, discusses the use of BTK inhibitors in frontline mantle cell lymphoma.

Mats Jerkeman, MD, discusses essential symptoms of MCL warranting referral for earlier diagnosis.

Ruby Arora, MD, discusses a study investigating survival outcomes and sociodemographic disparities among patients with MCL from 2000 to 2021.

BTK inhibitors were associated with lower health care resource utilization vs other regimens in mantle cell lymphoma.

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in August 2025.

A phase 1/2 trial met its primary end point of ORR with sonrotoclax in patients with relapsed/refractory MCL.

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

Martin Dreyling, MD, PhD, discusses the efficacy of first-line acalabrutinib plus BR in high-risk patients with mantle cell lymphoma.

Mats Jerkeman, MD, discusses the importance of conducting further research to classify the biological heterogeneity within MCL.

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.